B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on NGM Biopharmaceuticals (NASDAQ:NGM) Inc on Tuesday, setting a price target of $38, which is approximately 52.06% above the present share price of $24.99.
Mamtani expects NGM Biopharmaceuticals Inc to post earnings per share (EPS) of -$0.43 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in NGM Biopharmaceuticals, with an average price target of $42.75.
The analysts price targets range from a high of $50 to a low of $38.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $23.48 million and a net profit of -$29.96 million. The company's market cap is $1.86 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 34.2% and a 60.13% success rate.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.